Revolution Medicines, Inc. (RVMD)

NASDAQ: RVMD · Real-Time Price · USD

190.95

-5.99 (-3.04%)

At close: Sep 18, 2026, 4:00 PM EDT

190.96

+0.01 (0.00%)

After-hours: Sep 18, 2026, 7:56 PM EDT

Revolution Medicines Employees

Revolution Medicines had 883 employees as of December 31, 2025. The number of employees increased by 349 or 65.36% compared to the previous year.

Employees

883

Change (1Y)

349

Growth (1Y)

65.36%

Revenue / Employee

n/a

Profits / Employee

-$2,002,588

Market Cap

40.93B

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)
Dec 31, 2025	883	349	65.36%
Dec 31, 2024	534	156	41.27%
Dec 31, 2023	378	132	53.66%
Dec 31, 2022	246	58	30.85%
Dec 31, 2021	188	63	50.40%
Dec 31, 2020	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro

Related Stocks

Company Name	Employees
Regeneron Pharmaceuticals	15,410
BeOne Medicines AG	12,000
BioNTech SE	7,807
Moderna	4,700
Genmab	3,119
Incyte	2,844
Alnylam Pharmaceuticals	2,500
argenx SE	1,863

Employee Rankings

RVMD News

4 days ago - Revolution Medicines gets orphan designation for pancreatic cancer treatment - TheFly
5 days ago - Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA - TheFly
5 days ago - Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer - GlobeNewsWire
10 days ago - Revolution Medicines initiated with an Overweight at Morgan Stanley - TheFly
11 days ago - Revolution Medicines price target raised to $230 from $215 at Stifel - TheFly
15 days ago - Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off. - Business Insider
17 days ago - NEJM publishes Phase 1/2 clinical data on daraxonrasib - TheFly
17 days ago - New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer - GlobeNewsWire